385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study

F. Barlesi; Jürgen Wolf; M-J Ahn; Robert Doebele; L. Paz-Ares; Christian Rolfo; Salvatore Siena; T. Seto; Yuichiro Ohe; Sai-Hong Ou; Matthew Krebs; A. Kapre; E. Piault-Louis; S. McCallum; S. Osborne; A. Aziez; Alexander Edward Drilon

doi:10.1016/j.annonc.2020.10.379

385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study

F. Barlesi, Jürgen Wolf, M-J Ahn, Robert Doebele, L. Paz-Ares, Christian Rolfo, Salvatore Siena, T. Seto, Yuichiro Ohe, Sai-Hong Ou, Matthew Krebs, A. Kapre, E. Piault-Louis, S. McCallum, S. Osborne, A. Aziez, Alexander Edward Drilon

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1391-S1392
Number of pages	2
Journal	Annals of Oncology
Volume	31
Issue number	Supplement 6
DOIs	https://doi.org/10.1016/j.annonc.2020.10.379
Publication status	Published - 1 Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2020.10.379

Cite this

Barlesi, F., Wolf, J., Ahn, M.-J., Doebele, R., Paz-Ares, L., Rolfo, C., Siena, S., Seto, T., Ohe, Y., Ou, S.-H., Krebs, M., Kapre, A., Piault-Louis, E., McCallum, S., Osborne, S., Aziez, A., & Drilon, A. E. (2020). 385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. Annals of Oncology, 31(Supplement 6), S1391-S1392. https://doi.org/10.1016/j.annonc.2020.10.379

@article{e64e615a243b49b292fc057a1589a982,

title = "385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study",

author = "F. Barlesi and J{\"u}rgen Wolf and M-J Ahn and Robert Doebele and L. Paz-Ares and Christian Rolfo and Salvatore Siena and T. Seto and Yuichiro Ohe and Sai-Hong Ou and Matthew Krebs and A. Kapre and E. Piault-Louis and S. McCallum and S. Osborne and A. Aziez and Drilon, {Alexander Edward}",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/j.annonc.2020.10.379",

language = "English",

volume = "31",

pages = "S1391--S1392",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Supplement 6",

}

Barlesi, F, Wolf, J, Ahn, M-J, Doebele, R, Paz-Ares, L, Rolfo, C, Siena, S, Seto, T, Ohe, Y, Ou, S-H, Krebs, M, Kapre, A, Piault-Louis, E, McCallum, S, Osborne, S, Aziez, A & Drilon, AE 2020, '385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study', Annals of Oncology, vol. 31, no. Supplement 6, pp. S1391-S1392. https://doi.org/10.1016/j.annonc.2020.10.379

385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. / Barlesi, F.; Wolf, Jürgen; Ahn, M-J et al.
In: Annals of Oncology, Vol. 31, No. Supplement 6, 01.11.2020, p. S1391-S1392.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 385P Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study

AU - Barlesi, F.

AU - Wolf, Jürgen

AU - Ahn, M-J

AU - Doebele, Robert

AU - Paz-Ares, L.

AU - Rolfo, Christian

AU - Siena, Salvatore

AU - Seto, T.

AU - Ohe, Yuichiro

AU - Ou, Sai-Hong

AU - Krebs, Matthew

AU - Kapre, A.

AU - Piault-Louis, E.

AU - McCallum, S.

AU - Osborne, S.

AU - Aziez, A.

AU - Drilon, Alexander Edward

PY - 2020/11/1

Y1 - 2020/11/1

U2 - 10.1016/j.annonc.2020.10.379

DO - 10.1016/j.annonc.2020.10.379

M3 - Meeting Abstract

SN - 0923-7534

VL - 31

SP - S1391-S1392

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 6

ER -